Shubhnita Singh1, Ariane Bruder-Nascimento1, Eric J Belin de Chantemele2, Thiago Bruder-Nascimento3. 1. Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA; Center for Pediatrics Research in Obesity and Metabolism (CPROM), University of Pittsburgh, Pittsburgh, PA, USA. 2. Vascular Biology Center (VBC), Augusta University, Augusta, GA. 3. Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA; Center for Pediatrics Research in Obesity and Metabolism (CPROM), University of Pittsburgh, Pittsburgh, PA, USA; Richard King Mellon Institute for Pediatric Research, University of Pittsburgh, Pittsburgh, PA, USA; Vascular Medicine Institute (VMI), University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: bruder@pitt.edu.
Abstract
BACKGROUND: Chemokine (C- Cmotif) ligand 5 (CCL5) and its receptor C-C motif chemokine receptor 5 (CCR5), have been broadly studied in conjunction with infectious pathogens, however, their involvement in cardiovascular disease is not completely understood. NADPH oxidases (Noxs) are the major source of reactive oxygen species (ROS) in the vasculature. Whether the activation of Noxs is CCL5/CCR5 sensitive and whether such interaction initiates vascular injury is unknown. We investigated whether CCL5/CCR5 leads to vascular damage by activating Noxs. MATERIAL AND METHODS: We used rat aortic smooth muscle cells (RASMC) to investigate the molecular mechanisms by which CCL5 leads to vascular damage and carotid ligation (CL) to analyze the effects of blocking CCR5 on vascular injury. RESULTS: CCL5 induced Nox1 expression in concentration and time-dependent manners, with no changes in Nox2 or Nox4. Maraviroc pre-treatment (CCR5 antagonist, 40uM) blunted CCL5-induced Nox1 expression. Furthermore, CCL5 incubation led to ROS production and activation of Erk1/2 and NFkB, followed by increased vascular cell migration, proliferation, and inflammatory markers. Notably, Nox1 inhibition (GKT771, 10uM) blocked CCL5-dependent effects. In vivo, CL induced pathological vascular remodeling and inflammatory genes and increased Nox1 and CCR5 expression. Maraviroc treatment (25 mg/Kg/day) reduced pathological vascular growth and Nox1 expression. CONCLUSIONS: Our findings suggest that CCL5 activates Nox1 in the vasculature, leading to vascular injury likely via NFkB and Erk1/2. Herein, we place CCR5 antagonists and/or Nox1 inhibitors might be preeminent antiproliferative compounds to reduce the cardiovascular risk associated with medical procedures (e.g. angioplasty) and vascular diseases associated with vascular hyperproliferation.
BACKGROUND: Chemokine (C- Cmotif) ligand 5 (CCL5) and its receptor C-C motif chemokine receptor 5 (CCR5), have been broadly studied in conjunction with infectious pathogens, however, their involvement in cardiovascular disease is not completely understood. NADPH oxidases (Noxs) are the major source of reactive oxygen species (ROS) in the vasculature. Whether the activation of Noxs is CCL5/CCR5 sensitive and whether such interaction initiates vascular injury is unknown. We investigated whether CCL5/CCR5 leads to vascular damage by activating Noxs. MATERIAL AND METHODS: We used rat aortic smooth muscle cells (RASMC) to investigate the molecular mechanisms by which CCL5 leads to vascular damage and carotid ligation (CL) to analyze the effects of blocking CCR5 on vascular injury. RESULTS: CCL5 induced Nox1 expression in concentration and time-dependent manners, with no changes in Nox2 or Nox4. Maraviroc pre-treatment (CCR5 antagonist, 40uM) blunted CCL5-induced Nox1 expression. Furthermore, CCL5 incubation led to ROS production and activation of Erk1/2 and NFkB, followed by increased vascular cell migration, proliferation, and inflammatory markers. Notably, Nox1 inhibition (GKT771, 10uM) blocked CCL5-dependent effects. In vivo, CL induced pathological vascular remodeling and inflammatory genes and increased Nox1 and CCR5 expression. Maraviroc treatment (25 mg/Kg/day) reduced pathological vascular growth and Nox1 expression. CONCLUSIONS: Our findings suggest that CCL5 activates Nox1 in the vasculature, leading to vascular injury likely via NFkB and Erk1/2. Herein, we place CCR5 antagonists and/or Nox1 inhibitors might be preeminent antiproliferative compounds to reduce the cardiovascular risk associated with medical procedures (e.g. angioplasty) and vascular diseases associated with vascular hyperproliferation.
Authors: Gerd Fätkenheuer; Anton L Pozniak; Margaret A Johnson; Andreas Plettenberg; Schlomo Staszewski; Andy I M Hoepelman; Michael S Saag; Frank D Goebel; Jürgen K Rockstroh; Bruce J Dezube; Tim M Jenkins; Christine Medhurst; John F Sullivan; Caroline Ridgway; Samantha Abel; Ian T James; Mike Youle; Elna van der Ryst Journal: Nat Med Date: 2005-10-05 Impact factor: 53.440
Authors: Roy M Gulick; Jacob Lalezari; James Goodrich; Nathan Clumeck; Edwin DeJesus; Andrzej Horban; Jeffrey Nadler; Bonaventura Clotet; Anders Karlsson; Michael Wohlfeiler; John B Montana; Mary McHale; John Sullivan; Caroline Ridgway; Steve Felstead; Michael W Dunne; Elna van der Ryst; Howard Mayer Journal: N Engl J Med Date: 2008-10-02 Impact factor: 91.245
Authors: Sung W Choi; Gerhard C Hildebrandt; Krystyna M Olkiewicz; David A Hanauer; Meghana N Chaudhary; Ines A Silva; Clare E Rogers; Daphne T Deurloo; Jacki M Fisher; Chen Liu; David Adams; Stephen W Chensue; Kenneth R Cooke Journal: Blood Date: 2007-07-19 Impact factor: 22.113
Authors: Thiago Bruder-Nascimento; Jessica L Faulkner; Stephen Haigh; Simone Kennard; Galina Antonova; Vijay S Patel; David J R Fulton; Weiqin Chen; Eric J Belin de Chantemèle Journal: Hypertension Date: 2019-10-28 Impact factor: 10.190
Authors: Min Zhang; Heloise Mongue-Din; Daniel Martin; Norman Catibog; Ioannis Smyrnias; Xiaohong Zhang; Bin Yu; Minshu Wang; Ralf P Brandes; Katrin Schröder; Ajay M Shah Journal: Cardiovasc Res Date: 2018-03-01 Impact factor: 10.787
Authors: Thiago Bruder-Nascimento; Glaucia E Callera; Augusto C Montezano; Eric J Belin de Chantemele; Rita C Tostes; Rhian M Touyz Journal: Life Sci Date: 2019-02-02 Impact factor: 5.037